August 23, 2017 4:59 AM ET

Biotechnology

Company Overview of Therapix Biosciences Ltd.

Company Overview

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Tel Aviv, Israel.

5 Azrieli Center (Square Tower)

27th Floor

Tel Aviv,  6702501

Israel

Founded in 2004

5 Employees

Phone:

972 3 616 7055

Fax:

972 3 616 7056

Key Executives for Therapix Biosciences Ltd.

Chief Executive Officer
Age: 37
Total Annual Compensation: $190.0K
Chief Strategy Officer
Age: 65
Total Annual Compensation: $25.0K
Chief Technology Officer
Age: 49
Total Annual Compensation: $117.0K
Compensation as of Fiscal Year 2016.

Therapix Biosciences Ltd. Key Developments

Therapix Biosciences Ltd. Reports Unaudited Earnings Results for the Three Months and Six Months Ended June 30, 2017

Therapix Biosciences Ltd. reported unaudited earnings results for the three months and six months ended June 30, 2017. The company reported net loss of $1.9 million, or $0.54 per ADS, for the three months ended June 30, 2017, compared to a net loss of $0.5 million, or $0.61 per ADS, for the three months ended June 30, 2016. This period's net loss included $0.44 million of exchange rate differences on balances of cash and cash equivalents, versus none incurred during the corresponding period in 2016. Net cash used in operating activities was $1.936 million compared to $0.430 million a year ago. Purchase of equipment was $7,000. For the six month, the company reported net loss $2.5 million or $1.08 per ADS compared to $1.0 million or $1.18 a year ago. Net cash used in operating activities was $2.130 million compared to $0.765 million a year ago. Purchase of equipment was $7,000 compared to $4,000 a year ago.

Therapix Biosciences Ltd., Q2 2017 Earnings Call, Aug 10, 2017

Therapix Biosciences Ltd., Q2 2017 Earnings Call, Aug 10, 2017

Cure Pharmaceutical & Therapix Biosciences Signs MOU with Assuta Medical Center to Develop Therapeutic Products in Fields of Personalized Medicine & Cannabinoids

CURE Pharmaceutical and Therapix Biosciences signed a memorandum of understanding to enter into a research collaboration with Assuta Medical Centers Ltd. The companies will collaborate to advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids. As agreed to in the MOU, the Companies intend to formalize the pooling of professional, scientific, financial resources and expertise, in order to benefit from each of its respective advantages and capabilities to develop new therapeutic products in the fields of personalized medicine and cannabinoids. Specifically, CURE and Therapix will provide support and expertise in the development of pharmaceutical products, while Assuta will support the early research and development of potential projects through its research and facilities.

Similar Private Companies By Industry

Company Name Region
3PLW Ltd. Middle East/Africa
Accelerated Evolution Biotechnologies Ltd Middle East/Africa
Adante Ltd. Middle East/Africa
Advanced Biotechnology Ltd. Middle East/Africa
Advanced Medical Analysis (AMA) Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
Private Placement
February 14, 2017
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Therapix Biosciences Ltd., please visit www.therapixbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.